We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shortage of balm

4 February 2015 By Robert Cyran

Its hep C drug helped the $145 bln biotech quadruple fourth-quarter earnings and plan for a big buyback. Gilead’s stock sank 10 pct, though, because it’s going to discount the treatment sharply this year. Cures fuel price wars because there’s no repeat business to worry about.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)